# US 2018/0023082 A1 · VARIANT RNAi

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2018/0023082 A1
- Document ID: US20180023082A1
- Status: Published application
- Kind: A1
- Application number: 15/549,895
- Filed: 2016-02-09
- Published: 2018-01-25
- Earliest claimed: 2015-02-10
- Assignees: Genzyme Corporation
- Applicants: Genzyme Corporation
- Inventors: Lisa M. STANEK; Adam PALERMO; Brenda RICHARDS; Sergio Pablo SARDI; Catherine O'RIORDAN; Antonius SONG
- Web page: https://patentgrep.com/patent/US20180023082A1

## CPC

- C12N 15/113: Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)}
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/08: Antiepileptics; Anticonvulsants
- A61P 25/14: for treating abnormal movements, e.g. chorea, dyskinesia
- A61P 25/16: Anti-Parkinson drugs
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 35/00: Antineoplastic agents
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C12N 2310/14: interfering nucleic acids [NA]
- C12N 2310/531: Stem-loop; Hairpin
- C12N 2310/533: having a mismatch or nick in at least one of the strands
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Provided herein are RNAi molecules including a first strand containing a guide sequence and a second strand comprising a non-guide sequence where the non-guide sequence contains a bulge opposite the seed region of the guide sequences; e.g., opposite the cleavage sequence. In some aspects, the invention provides RNAi for treating Huntington's disease. Further provided herein are expression cassettes, vectors (e.g., rAAV, recombinant adenoviral, recombinant lentiviral, and recombinant HSV vectors), cells, viral particles, and pharmaceutical compositions containing the RNAi. Yet further provided herein are methods and kits related to the use of the RNAi, for example, to treat Huntington's disease.

## Claims

### Claim 1

An RNAi comprising a first strand and a second strand, wherein
a) the first strand and the second strand form a duplex;
b) the first strand comprises a guide region of at least 19 bases, wherein the guide region comprises a seed region comprising bases 1−N of the guide strand, wherein N=7 or N=8; and
c) the second strand comprises a non-guide region of at least 19 bases, wherein the non-guide region comprises a bulge sequence opposite of any one or more of bases 1−(N+2) of the guide region in the duplex.

### Claim 2 (depends on 1)

The RNAi of claim 1, wherein N=7 and the bulge is opposite base 1, 2, 3, 4, 5, 6, 7, 8, or 9 of the guide region.

### Claim 3 (depends on 1)

The RNAi of claim 1, wherein N=8 and the bulge is opposite base 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 of the guide region.

### Claim 4 (depends on 1, 2, 3)

The RNAi of any one of claims 1-3, wherein the bulge is opposite base 1 or base N+2 of the guide region.

### Claim 5

An RNAi comprising a first strand and a second strand, wherein
a) the first strand and the second strand form a duplex;
b) the first strand comprises a guide region of at least 19 bases, wherein the guide region comprises a seed region comprising bases 1−N of the guide strand, wherein N=7 or N=8; and
c) the second strand comprises a non-guide region of at least 19 bases, wherein the non-guide region comprises a bulge sequence opposite of any one or more of bases 1−(N+1) of the guide region in the duplex.

### Claim 6 (depends on 5)

The RNAi of claim 5, wherein N=7 and the bulge is opposite base 1, 2, 3, 4, 5, 6, 7, or 8 of the guide region.

### Claim 7 (depends on 5)

The RNAi of claim 5, wherein N=8 and the bulge is opposite base 1, 2, 3, 4, 5, 6, 7, 8, or 9 of the guide region.

### Claim 8 (depends on 5, 6, 7)

The RNAi of any one of claims 5-7, wherein the bulge is opposite base 1 or base N+1 of the guide region.

### Claim 9

An RNAi comprising a first strand and a second strand, wherein
a) the first strand and the second strand form a duplex;
b) the first strand comprises a guide region of at least 19 bases, wherein the guide region comprises a seed region comprising bases 1−N of the guide strand, wherein N=7 or N=8; and
c) the second strand comprises a non-guide region of at least 19 bases, wherein the non-guide region comprises a bulge sequence opposite of any one or more of bases 1−N of the guide region in the duplex.

### Claim 10 (depends on 9)

The RNAi of claim 9, wherein N=7 and the bulge is opposite base 1, 2, 3, 4, 5, 6 or 7 of the guide region.

### Claim 11 (depends on 9)

The RNAi of claim 9, wherein N=8 and the bulge is opposite base 1, 2, 3, 4, 5, 6, 7 or 8 of the guide region.

### Claim 12 (depends on 9, 10, 11)

The RNAi of any one of claims 9-11, wherein the bulge is opposite base 1 or base N of the guide region.

### Claim 13 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12)

The RNAi of any one of claims 1-12, wherein the bulge is opposite base 1 of the guide region.

### Claim 14 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13)

The RNAi of any one of claims 1-13, wherein the bulge is formed by one or more bases of the non-guide strand in the duplex that lack a complementary base on the guide region, wherein the bulge is flanked by bases that do basepair with the guide strand.

### Claim 15 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14)

The RNAi of any one of claims 1-14, wherein the bulge comprises 1 to 10 nucleotides.

### Claim 16 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15)

The RNAi of any one of claims 1-15, wherein the bulge comprises 1-3 nucleotides.

### Claim 17 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16)

The RNAi of any one of claims 1-16, wherein RNAi comprises a second bulge, wherein the second bulge is located on the first strand in the guide region located 3′ to the seed region.

### Claim 18 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17)

The RNAi of any one of claims 1-17, wherein the duplex is between 19 and 25 or 19 and 23 base pairs in length.

### Claim 19 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18)

The RNAi of any one of claims 1-18, wherein the first and/or second strand further comprises a 3′ overhang region, a 5′ overhang region, or both 3′ and 5′ overhang regions.

### Claim 20 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19)

The RNAi of any one of claims 1-19, wherein the first strand and the second strand are linked by means of RNA linker capable of forming a loop structure.

### Claim 21 (depends on 20)

The RNAi of claim 20, wherein RNA linker comprises from 4 to 50 nucleotides.

### Claim 22 (depends on 20, 21)

The RNAi of claim 20 or 21, wherein the loop structure comprises 4 to 20 nucleotides

### Claim 23 (depends on 20, 21, 22)

The RNAi of any one of claims 20-22, wherein the RNAi comprises 5′ to 3′ the second strand, the RNA linker, and the first strand.

### Claim 24 (depends on 20, 21, 22)

The RNAi of any one of claims 20-22, wherein the RNAi comprises 5′ to 3′ the first strand, the RNA linker, and the second strand.

### Claim 25 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24)

The RNAi of any one of claims 1-24, wherein the sequence is improved to reduce off-target gene silencing.

### Claim 26 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25)

The RNAi of any one of claims 1-25, wherein the sequence comprises one or more CpG motifs.

### Claim 27 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26)

The RNAi of any one of claims 1-26, wherein the sequence comprises one or more CpG motifs in the seed region.

### Claim 28 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27)

The RNAi of any one of claims 1-27, wherein the RNAi is a small inhibitory RNA (siRNA), a microRNA (miRNA), or a small hairpin RNA (shRNA).

### Claim 29 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28)

The RNAi of any one of claims 1-28, wherein the RNAi targets RNA encoding a polypeptide associated with a disorder.

### Claim 30 (depends on 29)

The RNAi of claim 29, wherein the disorder is a CNS disorder.

### Claim 31 (depends on 29, 30)

The RNAi of claim 29 or 30, wherein the disorder is lysosomal storage disease (LSD), Huntington's disease, epilepsy, Parkinson's disease, Alzheimer's disease, stroke, corticobasal degeneration (CBD), corticogasal ganglionic degeneration (CBGD), frontotemporal dementia (FTD), multiple system atrophy (MSA), progressive supranuclear palsy (PSP) or cancer of the brain.

### Claim 32 (depends on 29, 30, 31)

The RNAi of anyone of claims 29-31, wherein the disorder is Huntington's disease.

### Claim 33 (depends on 32)

The RNAi of claim 32, wherein the polypeptide is huntingtin.

### Claim 34 (depends on 33)

The RNAi of claim 33, wherein the huntingtin comprises a mutation associated with Huntington's disease.

### Claim 35 (depends on 32, 33, 34)

The RNAi of any one of claims 32-34, wherein the guide region comprises the sequence 5′-UAGACAAUGAUUCACACGGU-3′ (SEQ ID NO:1) and the non-guide region comprises the sequence 5′-ACCGUGUGUCAUUGUCUAA-3′ (SEQ ID NO:2).

### Claim 36 (depends on 32, 33, 34)

The RNAi of any one of claims 32-34, wherein the guide region comprises the sequence 5′-UCGACAAUGAUUCACACGGU-3′ (SEQ ID NO:15) and the non-guide region comprises the sequence 5′-ACCGUGUGUCAUUGUCGAA-3′ (SEQ ID NO:16).

### Claim 37 (depends on 32, 33, 34)

The RNAi of any one of claims 32-34, wherein the guide region comprises the sequence 5′-UAGACGAUGAUUCACACGGU-3′ (SEQ ID NO:17) and the non-guide region comprises the sequence 5′-ACCGUGUGUCAUCGUCUAA-3′ (SEQ ID NO:18).

### Claim 38 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37)

A method to reduce the toxicity of a RNAi comprising introducing a bulge in the non-guide region of the RNAi to generate a RNAi of any one of claims 1-37.

### Claim 39 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38)

An expression construct comprising nucleic acid encoding the RNAi of any one of claims 1-38.

### Claim 40 (depends on 39)

The expression construct of claim 39 wherein the nucleic acid encoding the RNAi comprises a miRNA scaffold.

### Claim 41 (depends on 39, 40)

The expression construct of claim 39 or 40, wherein the nucleic acid encoding the RNAi is operably linked to a promoter.

### Claim 42 (depends on 41)

The expression construct of claim 41, wherein the promoter is selected from a cytomegalovirus (CMV) immediate early promoter, an RSV LTR, a MoMLV LTR, a phosphoglycerate kinase-1 (PGK) promoter, a simian virus 40 (SV40) promoter, a CK6 promoter, a transthyretin promoter (TTR), a TK promoter, a tetracycline responsive promoter (TRE), an HBV promoter, an hAAT promoter, a LSP promoter, a chimeric liver-specific promoter (LSP), an E2F promoter, a telomerase (hTERT) promoter; a cytomegalovirus enhancer/chicken beta-actin/Rabbit β-globin promoter (CAG) promoter, an elongation factor 1-alpha promoter (EF1-alpha) promoter, a human β-glucuronidase promoter, a chicken β-actin (CBA) promoter, a retroviral Rous sarcoma virus (RSV) LTR promoter, a dihydrofolate reductase promoter, and a 13-actin promoter.

### Claim 43 (depends on 39, 40, 41, 42)

The expression construct of any one of claims 39-42, wherein the expression construct further comprises a polyadenylation signal.

### Claim 44 (depends on 43)

The expression construct of claim 43 wherein the polyadenylation signal is a bovine growth hormone polyadenylation signal, an SV40 polyadenylation signal, or a HSV TK pA.

### Claim 45 (depends on 39, 40, 41, 42, 43, 44)

A vector comprising the expression construct of any one of claims 39-44.

### Claim 46 (depends on 45)

The vector of claim 45, wherein the vector is a recombinant adeno-associated virus (rAAV) vector, a recombinant adenoviral vector, a recombinant lentiviral vector or a recombinant herpes simplex virus (HSV) vector.

### Claim 47 (depends on 46)

The vector of claim 46, wherein the vector is a recombinant adenoviral vector.

### Claim 48 (depends on 47)

The vector of claim 47, wherein the recombinant adenoviral vector is derived from Adenovirus serotype 2, 1, 5, 6, 19, 3, 11, 7, 14, 16, 21, 12, 18, 31, 8, 9, 10, 13, 15, 17, 19, 20, 22, 23, 24-30, 37, 40, 41, AdHu2, AdHu 3, AdHu4, AdHu24, AdHu26, AdHu34, AdHu35, AdHu36, AdHu37, AdHu41, AdHu48, AdHu49, AdHu50, AdC6, AdC7, AdC69, bovine Ad type 3, canine Ad type 2, ovine Ad, or porcine Ad type 3.

### Claim 49 (depends on 47)

The vector of claim 47, wherein the recombinant adenoviral vector is derived from adenovirus serotype 2 or a variant of adenoviral serotype 5.

### Claim 50 (depends on 46)

The vector of claim 46, wherein the vector is a recombinant lentiviral vector.

### Claim 51 (depends on 50)

The vector of claim 50, wherein the recombinant lentiviral vector is derived from a lentivirus pseudotyped with vesicular stomatitis virus (VSV), lymphocytic choriomeningitis virus (LCMV), Ross river virus (RRV), Ebola virus, Marburg virus, Mokala virus, Rabies virus, RD114 or variants therein.

### Claim 52 (depends on 46)

The vector of claim 46, wherein the vector is a rHSV vector.

### Claim 53 (depends on 52)

The vector of claim 52, wherein the rHSV vector is derived from rHSV-1 or rHSV-2.

### Claim 54 (depends on 46)

The vector of claim 46, wherein the vector is a rAAV vector.

### Claim 55 (depends on 54)

The rAAV vector of claim 54, wherein the expression construct is flanked by one or more AAV inverted terminal repeat (ITR) sequences.

### Claim 56 (depends on 55)

The rAAV vector of claim 55, wherein the expression construct is flanked by two AAV ITRs.

### Claim 57 (depends on 55, 56)

The rAAV vector of claim 55 or 56, wherein the AAV ITRs are AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAVrh8, AAVrh8R, AAV9, AAV10, AAVrh10, AAV11, AAV12, AAV2R471A, AAV DJ, a goat AAV, bovine AAV, or mouse AAV serotype ITRs.

### Claim 58 (depends on 55, 56, 57)

The rAAV vector of any one of claims 55-57, wherein the AAV ITRs are AAV2 ITRs.

### Claim 59 (depends on 54, 55, 56, 57, 58)

The rAAV vector of any one of claims 54-58, wherein the vector further comprises a stuffer nucleic acid.

### Claim 60 (depends on 59)

The rAAV vector of claim 59, wherein the stuffer nucleic acid is located between the promoter and the nucleic acid encoding the RNAi.

### Claim 61 (depends on 54, 55, 56, 57, 58, 59, 60)

The rAAV vector of any one of claims 54-60, wherein the vector is a self-complementary rAAV vector.

### Claim 62 (depends on 61)

The rAAV vector of claim 61, wherein the vector comprises first nucleic acid sequence encoding the RNAi and a second nucleic acid sequence encoding a complement of the RNAi, wherein the first nucleic acid sequence can form intrastrand base pairs with the second nucleic acid sequence along most or all of its length.

### Claim 63 (depends on 62)

The rAAV vector of claim 62, wherein the first nucleic acid sequence and the second nucleic acid sequence are linked by a mutated AAV ITR, wherein the mutated AAV ITR comprises a deletion of the D region and comprises a mutation of the terminal resolution sequence.

### Claim 64 (depends on 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63)

A cell comprising the vector of any one of claims 45-53 or the rAAV vector of any one of claims 54-63.

### Claim 65 (depends on 45)

A viral particle comprising the vector of claim 45, wherein the viral particle is an AAV particle encapsidating the rAAV vector, an adenovirus particle encapsidating the recombinant adenoviral vector, a lentiviral particle encapsidating the recombinant lentiviral vector or an HSV particle encapsidating the recombinant HSV vector.

### Claim 66 (depends on 65)

The viral particle of claim 65, wherein the viral particle is an adenovirus particle encapsidating the recombinant adenoviral vector.

### Claim 67 (depends on 66)

The viral particle of claim 66, wherein the adenovirus particle comprises a capsid from Adenovirus serotype 2, 1, 5, 6, 19, 3, 11, 7, 14, 16, 21, 12, 18, 31, 8, 9, 10, 13, 15, 17, 19, 20, 22, 23, 24-30, 37, 40, 41, AdHu2, AdHu 3, AdHu4, AdHu24, AdHu26, AdHu34, AdHu35, AdHu36, AdHu37, AdHu41, AdHu48, AdHu49, AdHu50, AdC6, AdC7, AdC69, bovine Ad type 3, canine Ad type 2, ovine Ad, or porcine Ad type 3.

### Claim 68 (depends on 66)

The viral particle of claim 66, wherein the adenovirus particle comprises an adenovirus serotype 2 capsid or a variant of an adenoviral serotype 5 capsid.

### Claim 69 (depends on 66)

The viral particle of claim 66, wherein the viral particle is a lentiviral particle encapsidating the recombinant lentiviral vector.

### Claim 70 (depends on 69)

The viral particle of claim 69, wherein the lentiviral particle comprises a capsid pseudotyped with vesicular stomatitis virus (VSV), lymphocytic choriomeningitis virus (LCMV), Ross river virus (RRV), Ebola virus, Marburg virus, Mokala virus, Rabies virus, RD114 or variants therein.

### Claim 71 (depends on 66)

The viral particle of claim 66, wherein the viral particle is a HSV particle.

### Claim 72 (depends on 71)

The viral particle of claim 71, wherein the HSV particle is a rHSV-1 particle or a rHSV-2 particle.

### Claim 73 (depends on 54, 55, 56, 57, 58, 59, 60, 61, 62, 63)

A recombinant AAV particle comprising the rAAV vector of any one of claims 54-63.

### Claim 74 (depends on 73)

The rAAV particle of claim 73, wherein the AAV viral particle comprises an AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAVrh8, AAVrh8R, AAV9, AAV10, AAVrh10, AAV11, AAV12, AAV2R471A, AAV2/2-7m8, AAV DJ, AAV2 N587A, AAV2 E548A, AAV2 N708A, AAV V708K, a goat AAV, AAV1/AAV2 chimeric, bovine AAV, or mouse AAV capsid rAAV2/HBoV1 serotype capsid.

### Claim 75 (depends on 73, 74)

The rAAV particle of claim 73 or 74, wherein the ITR and the capsid of the rAAV viral particle are derived from the same AAV serotype.

### Claim 76 (depends on 73, 74)

The rAAV particle of claim 73 or 74, wherein the ITR and the capsid of the rAAV viral particle are derived from different AAV serotypes.

### Claim 77 (depends on 76)

The rAAV particle of claim 76, wherein the ITR is derived from AAV2 and the capsid of the rAAV particle is derived from AAV1.

### Claim 78 (depends on 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77)

A composition comprising the viral particle of any one of claims 65-72 or the rAAV particle of any one of claims 73-77.

### Claim 79 (depends on 78)

The composition of claim 78, wherein the composition further comprises a pharmaceutically acceptable carrier.

### Claim 80 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79)

A method for inhibiting or reducing the expression of a polypeptide in a mammal disease comprising administering to the mammal the RNAi of any one of claims 1-37; the expression construct of any one of claims 39-44; the vector of any one of claims 45-54; the rAAV vector of any one of claims 55-63; the viral particle of any one of claims 65-72; the rAAV particle of any one of claims 73-77; or the composition of claim 78 or 79, wherein the RNAi targets an RNA encoding the polypeptide.

### Claim 81 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79)

A method for inhibiting the accumulation of a polypeptide in a cell of a mammal comprising administering to the mammal the RNAi of any one of claims 1-37; the expression construct of any one of claims 39-44; the vector of any one of claims 45-53; the rAAV vector of any one of claims 54-63; the viral particle of any one of claims 65-72; the rAAV particle of any one of claims 73-77; or the composition of claim 78 or 79, wherein the RNAi targets an RNA encoding the polypeptide.

### Claim 82 (depends on 80, 81)

The method of claim 80 or 81, wherein the mammal is a human.

### Claim 83 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82)

Use of the RNAi of any one of claims 1-37; the expression construct of any one of claims 39-44; the vector of any one of claims 45-53; the rAAV vector of any one of claims 54-63; the viral particle of any one of claims 65-72; the rAAV particle of any one of claims 73-77; or the composition of claim 78 or 79, in the manufacture of a medicament for use in the method of any one of claims 80-82.

### Claim 84 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82)

The RNAi of any one of claims 1-37; the expression construct of any one of claims 39-44; the vector of any one of claims 45-53; the rAAV vector of any one of claims 54-63; the viral particle of any one of claims 65-72; the rAAV particle of any one of claims 73-77; or the composition of claim 78 or 79 for use in the method of any one of claims 80-82.

### Claim 85 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79)

A kit for inducing RNA interference in a mammal comprising the RNAi of any one of claims 1-37; the expression construct of any one of claims 39-44; the vector of any one of claims 45-53; the rAAV vector of any one of claims 54-63; the viral particle of any one of claims 65-72; the rAAV particle of any one of claims 73-77; or the composition of claim 78 or 79.

### Claim 86 (depends on 85)

The kit of claim 85, wherein the mammal is a human.

### Claim 87 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82)

A kit for use in the method of any one of claims 80-82 comprising the RNAi of any one of claims 1-37; the expression construct of any one of claims 39-44; the vector of any one of claims 45-53; the rAAV vector of any one of claims 54-63; the viral particle of any one of claims 65-72; the rAAV particle of any one of claims 73-77; or the composition of claim 78 or 79.

### Claim 88

An RNAi comprising a first strand comprising a guide region which comprises the sequence 5′-UAGACAAUGAUUCACACGGU-3′ (SEQ ID NO:1) and a second strand comprising a non-guide region which comprises the sequence 5′-ACCGUGUGUCAUUGUCUAA-3′ (SEQ ID NO:2), wherein the first strand and second strand form a duplex and wherein the A residue at residue 18 or residue 19 of the second strand forms a bulge in the non-guide region.

### Claim 89 (depends on 88)

The RNAi of claim 88, wherein the guide region comprises a nucleic acid sequence having about 90% identity to SEQ ID NO:1.

### Claim 90 (depends on 88)

The RNAi of claim 88, wherein the non-guide region comprises a nucleic acid sequence having about 90% identity to SEQ ID NO:2.

### Claim 91 (depends on 88, 89, 90)

The RNAi of any one of claims 88-90, wherein the sequence is improved to reduce off-target gene silencing.

### Claim 92 (depends on 88, 89, 90, 91)

The RNAi of any one of claims 88-91, wherein sequence comprises one or more CpG motifs.

### Claim 93 (depends on 88, 89, 90, 91, 92)

The RNAi of any one of claims 88-92, wherein the sequence comprises one or more CpG motifs in a seed region.

### Claim 94

An RNAi comprising a first strand comprising a guide region which comprises the sequence 5′-UCGACAAUGAUUCACACGGU-3′ (SEQ ID NO:15) and a second strand comprising a non-guide region which comprises the sequence 5′-ACCGUGUGUCAUUGUCGAA-3′ (SEQ ID NO:16), wherein the first strand and second strand form a duplex and wherein the A residue at residue 18 or residue 19 of the second strand forms a bulge in the non-guide region.

### Claim 95

An RNAi comprising a first strand comprising a guide region which comprises the sequence 5′-UAGACGAUGAUUCACACGGU-3′ (SEQ ID NO:17) and a second strand comprising a non-guide region which comprises the sequence 5′-ACCGUGUGUCAUCGUCUAA-3′ (SEQ ID NO:18), wherein the first strand and second strand form a duplex and wherein the A residue at residue 18 or residue 19 of the second strand forms a bulge in the non-guide region.

### Claim 96

The RNAi of claim wherein the guide region comprises a nucleic acid sequence having about 90% identity to SEQ ID NO:15 and the non-guide region comprises a nucleic acid sequence having about 90% identity to SEQ ID NO:16 or a nucleic acid sequence having about 90% identity to SEQ ID NO:17 and the non-guide region comprises a nucleic acid sequence having about 90% identity to SEQ ID NO:18.

### Claim 97 (depends on 88, 89, 90, 91, 92, 93, 94, 95, 96)

The RNAi of any one of claims 88-96, wherein U residues at residues 11 and 12 of the guide region forms a bulge in the guide region.

### Claim 98 (depends on 88, 89, 90, 91, 92, 93, 94, 95, 96, 97)

The RNAi of any one of claims 88-97, wherein the duplex is between 19 and 25 or 19 and 23 base pairs in length.

### Claim 99 (depends on 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98)

The RNAi of any one of claims 88-98, wherein the first and/or second strand further comprises a 3′ overhang region, a 5′ overhang region, or both 3′ and 5′ overhang regions.

### Claim 100 (depends on 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99)

The RNAi of any one of claims 88-99, wherein the first strand and the second strand are linked by means of a RNA linker capable of forming a loop structure.

### Claim 101 (depends on 100)

The RNAi of claim 100, wherein RNA linker capable of forming a loop structure comprises from 4 to 50 nucleotides.

### Claim 102 (depends on 100, 101)

The RNAi of claim 100 or 101, wherein RNA linker capable of forming a loop structure comprises from 4 to 20 nucleotides.

### Claim 103 (depends on 100, 101, 102)

The RNAi of any one of claims 100-102, wherein RNA linker capable of forming a loop structure comprises 13 nucleotides.

### Claim 104 (depends on 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103)

The RNAi of any one of claims 88-103, wherein the RNAi comprises the nucleotide sequence of SEQ ID NO:3.

### Claim 105 (depends on 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103)

The RNAi of claim of any one of claims 88-103, wherein the RNAi comprises a nucleotide sequence about 90% identical to the nucleotide sequence of SEQ ID NO:3.

### Claim 106 (depends on 88, 89, 90, 91, 92, 93, 94)

The RNAi of any one of claims 88-94, wherein the RNAi is a small inhibitory RNA (siRNA), a microRNA (miRNA), or a small hairpin RNA (shRNA).

### Claim 107 (depends on 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106)

An expression construct comprising nucleic acid encoding the RNAi of any one of claims 88-106.

### Claim 108 (depends on 107)

The expression construct of claim 107 wherein the nucleic acid encoding the RNAi comprises a miRNA scaffold.

### Claim 109 (depends on 108)

The expression construct of claim 108 wherein the nucleic acid encoding the RNAi comprises a miR-155 scaffold.

### Claim 110 (depends on 107, 108, 109)

The expression construct of any one of claims 107-109, wherein the nucleic acid encoding the RNAi is operably linked to a promoter.

### Claim 111 (depends on 110)

The expression construct of claim 110, wherein the promoter is capable of expressing the RNAi in the brain of a mammal.

### Claim 112 (depends on 110, 111)

The expression construct of claim 110 or 111, wherein the promoter is selected from a cytomegalovirus (CMV) immediate early promoter, an RSV LTR, a MoMLV LTR, a phosphoglycerate kinase-1 (PGK) promoter, a simian virus 40 (SV40) promoter, a CK6 promoter, a transthyretin promoter (TTR), a TK promoter, a tetracycline responsive promoter (TRE), an HBV promoter, an hAAT promoter, a LSP promoter, a chimeric liver-specific promoter (LSP), an E2F promoter, a telomerase (hTERT) promoter; a cytomegalovirus enhancer/chicken beta-actin/Rabbit β-globin promoter (CAG) promoter, an elongation factor 1-alpha promoter (EF1-alpha) promoter, a human β-glucuronidase promoter, a chicken β-actin (CBA) promoter, a retroviral Rous sarcoma virus (RSV) LTR promoter, a dihydrofolate reductase promoter, and a 13-actin promoter.

### Claim 113 (depends on 110, 111, 112)

The expression construct of any one of claims 110-112, wherein the promoter is a hybrid chicken β-actin promoter.

### Claim 114 (depends on 110, 111, 112, 113)

The expression construct of any one of claims 110-113, wherein the expression construct further comprises a polyadenylation signal.

### Claim 115 (depends on 114)

The expression construct of claim 114, wherein the polyadenylation signal is a bovine growth hormone polyadenylation signal.

### Claim 116 (depends on 107, 108, 109, 110, 111, 112, 113, 114, 115)

A vector comprising the expression construct of any one of claims 107-115.

### Claim 117 (depends on 116)

The vector of claim 116, wherein the vector is a recombinant adeno-associated virus (rAAV) vector, a recombinant adenoviral vector, a recombinant lentiviral vector or a recombinant herpes simplex virus (HSV) vector.

### Claim 118 (depends on 117)

The vector of claim 117, wherein the vector is a recombinant adenoviral vector.

### Claim 119 (depends on 118)

The vector of claim 118, wherein the recombinant adenoviral vector is derived from Adenovirus serotype 2, 1, 5, 6, 19, 3, 11, 7, 14, 16, 21, 12, 18, 31, 8, 9, 10, 13, 15, 17, 19, 20, 22, 23, 24-30, 37, 40, 41, AdHu2, AdHu 3, AdHu4, AdHu24, AdHu26, AdHu34, AdHu35, AdHu36, AdHu37, AdHu41, AdHu48, AdHu49, AdHu50, AdC6, AdC7, AdC69, bovine Ad type 3, canine Ad type 2, ovine Ad, or porcine Ad type 3.

### Claim 120 (depends on 119)

The vector of claim 119, wherein the recombinant adenoviral vector is derived from adenovirus serotype 2 or a variant of adenoviral serotype 5.

### Claim 121 (depends on 117)

The vector of claim 117, wherein the vector is a recombinant lentiviral vector.

### Claim 122 (depends on 121)

The vector of claim 121, wherein the recombinant lentiviral vector is derived from a lentivirus pseudotyped with vesicular stomatitis virus (VSV), lymphocytic choriomeningitis virus (LCMV), Ross river virus (RRV), Ebola virus, Marburg virus, Mokala virus, Rabies virus, RD114 or variants therein.

### Claim 123 (depends on 117)

The vector of claim 117, wherein the vector is a rHSV vector.

### Claim 124 (depends on 123)

The vector of claim 123, wherein the rHSV vector is derived from rHSV-1 or rHSV-2.

### Claim 125 (depends on 117)

The vector of claim 117, wherein the vector is a recombinant AAV (rAAV) vector.

### Claim 126 (depends on 125)

The rAAV vector of claim 125, wherein the expression construct is flanked by one or more AAV inverted terminal repeat (ITR) sequences.

### Claim 127 (depends on 126)

The rAAV vector of claim 126, wherein the expression construct is flanked by two AAV ITRs.

### Claim 128 (depends on 126, 127)

The rAAV vector of claim 126 or 127, wherein the AAV ITRs are AAV ITRs are AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAVrh8, AAVrh8R, AAV9, AAV10, AAVrh10, AAV11, AAV12, AAV2R471A, AAV DJ, a goat AAV, bovine AAV, or mouse AAV serotype ITRs.

### Claim 129 (depends on 125, 126, 127, 128)

The rAAV vector of any one of claims 125-128, wherein the AAV ITRs are AAV2 ITRs.

### Claim 130 (depends on 129)

The rAAV vector of claim 129, wherein the rAAV vector comprises 5′ to 3′ an AAV2 ITR, a promoter, nucleic acid encoding the RNAi, a polyadenylation signal, and an AAV2 ITR.

### Claim 131 (depends on 130)

The rAAV vector of claim 130 wherein the promoter is a CBA promoter.

### Claim 132 (depends on 130, 131)

The rAAV vector of claim 130 or 131, wherein the polyadenylation signal is a bovine growth hormone polyadenylation signal.

### Claim 133 (depends on 130, 131, 132)

The rAAV vector of any one of claims 130-132, wherein the rAAV vector comprises 5′ to 3′ an AAV2 ITR, the CBA promoter, nucleic acid encoding the RNAi, a bovine growth hormone polyadenylation signal, and an AAV2 ITR.

### Claim 134 (depends on 133)

The rAAV vector of claim 133, wherein the vector further comprise a stuffer nucleic acid.

### Claim 135 (depends on 133)

The rAAV vector of claim 133, wherein the stuffer nucleic acid comprises nucleic acid encoding a green fluorescent protein (GFP).

### Claim 136 (depends on 134, 135)

The rAAV vector of claim 134 or 135, wherein the stuffer nucleic acid is located between the promoter and the nucleic acid encoding the RNAi.

### Claim 137 (depends on 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136)

The rAAV vector of any one of claims 125-136, wherein the RNAi comprises the nucleotide sequence of SEQ ID NO:3.

### Claim 138 (depends on 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136)

The rAAV vector of any one of claims 125-136, wherein the RNAi comprises a nucleotide sequence about 90% identical to the nucleotide sequence of SEQ ID NO:3

### Claim 139 (depends on 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138)

The rAAV vector of any one of claims 125-138, wherein the vector is a self-complementary vector.

### Claim 140 (depends on 139)

The rAAV vector of claim 139, wherein the vector comprises first nucleic acid sequence encoding the RNAi and a second nucleic acid sequence encoding a complement of the RNAi, wherein the first nucleic acid sequence can form intrastrand base pairs with the second nucleic acid sequence along most or all of its length.

### Claim 141 (depends on 140)

The rAAV vector of claim 140, wherein the first nucleic acid sequence and the second nucleic acid sequence are linked by a mutated AAV ITR, wherein the mutated AAV ITR comprises a deletion of the D region and comprises a mutation of the terminal resolution sequence.

### Claim 142 (depends on 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141)

A cell comprising the vector of any one of claims 116-124 or the rAAV vector of any one of claims 125-141.

### Claim 143 (depends on 142)

The cell of claim 142, wherein the cell is a central nervous system (CNS) cell.

### Claim 144 (depends on 116)

A viral particle comprising the vector of claim 116, wherein the viral particle is an AAV particle encapsidating the rAAV vector, an adenovirus particle encapsidating the recombinant adenoviral vector, a lentiviral particle encapsidating the recombinant lentiviral vector or an HSV particle encapsidating the recombinant HSV vector.

### Claim 145 (depends on 144)

The viral particle of claim 144, wherein the viral particle is an adenovirus particle encapsidating the recombinant adenoviral vector.

### Claim 146 (depends on 145)

The viral particle of claim 145, wherein the adenovirus particle comprises a capsid from Adenovirus serotype 2, 1, 5, 6, 19, 3, 11, 7, 14, 16, 21, 12, 18, 31, 8, 9, 10, 13, 15, 17, 19, 20, 22, 23, 24-30, 37, 40, 41, AdHu2, AdHu 3, AdHu4, AdHu24, AdHu26, AdHu34, AdHu35, AdHu36, AdHu37, AdHu41, AdHu48, AdHu49, AdHu50, AdC6, AdC7, AdC69, bovine Ad type 3, canine Ad type 2, ovine Ad, or porcine Ad type 3.

### Claim 147 (depends on 146)

The viral particle of claim 146, wherein the adenovirus particle comprises an adenovirus serotype 2 capsid or a variant of an adenoviral serotype 5 capsid.

### Claim 148 (depends on 144)

The viral particle of claim 144, wherein the viral particle is a lentiviral particle encapsidating the recombinant lentiviral vector.

### Claim 149 (depends on 148)

The viral particle of claim 148, wherein the lentiviral particle comprises a capsid pseudotyped with vesicular stomatitis virus (VSV), lymphocytic choriomeningitis virus (LCMV), Ross river virus (RRV), Ebola virus, Marburg virus, Mokala virus, Rabies virus, RD114 or variants therein.

### Claim 150 (depends on 144)

The viral particle of claim 144, wherein the viral particle is a HSV particle.

### Claim 151 (depends on 150)

The viral particle of claim 150, wherein the HSV particle is a rHSV-1 particle or a rHSV-2 particle.

### Claim 152 (depends on 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141)

A recombinant AAV particle comprising the rAAV vector of any one of claims 125-141.

### Claim 153 (depends on 141)

The rAAV particle of claim 141, wherein the AAV viral particle comprises an AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAVrh8, AAVrh8R, AAV9, AAV10, AAVrh10, AAV11, AAV12, AAV2R471A, AAV2/2-7m8, AAV DJ, AAV2 N587A, AAV2 E548A, AAV2 N708A, AAV2 V708K, goat AAV, AAV1/AAV2 chimeric, bovine AAV, mouse AAV, or rAAV2/HBoV1 serotype capsid.

### Claim 154 (depends on 152, 153)

The rAAV particle of claim 152 or 153, wherein the ITR and the capsid of the rAAV viral particle are derived from the same AAV serotype.

### Claim 155 (depends on 152, 153)

The rAAV particle of claim 152 or 153, wherein the ITR and the capsid of the rAAV viral particles are derived from different AAV serotypes.

### Claim 156 (depends on 152, 153, 154, 155)

The rAAV particle of any one of claims 152-155, wherein the rAAV viral particle comprises AAV2 capsid.

### Claim 157 (depends on 156)

The rAAV particle of claim 156, wherein the rAAV viral particle comprises an AAV1 capsid, and wherein the vector comprises AAV2 ITRs.

### Claim 158 (depends on 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157)

A composition comprising the viral particle of any one of claims 144-151 or the rAAV particle of any one of claims 152-157.

### Claim 159 (depends on 158)

The composition of claim 158 further comprises a pharmaceutically acceptable carrier.

### Claim 160 (depends on 158, 159)

A method for treating Huntington's disease in a mammal comprising administering to the mammal the composition of claim 158 or 159.

### Claim 161 (depends on 158, 159)

A method for inhibiting the expression of htt in a mammal with Huntington's disease comprising administering to the mammal the composition of claim 158 or 159.

### Claim 162 (depends on 158, 159)

A method for inhibiting the accumulation of htt in a cell of a mammal with Huntington's disease comprising administering to the mammal the pharmaceutical composition of claim 158 or 159.

### Claim 163

A method for treating Huntington's disease in a mammal comprising administering to the mammal an RNAi comprising a first strand comprising a first nucleic acid comprising the sequence 5′-UAGACAAUGAUUCACACGGU-3′ (SEQ ID NO:1) and a second strand comprising a second nucleic acid comprising the sequence 5′-ACCGUGUGUCAUUGUCUAA-3′ (SEQ ID NO:2), wherein the A residue at residue 18 or residue 19 of the second strand does not form a basepair with a residue in the first strand.

### Claim 164

A method for inhibiting the expression of htt in a mammal with Huntington's disease comprising administering to the mammal an RNAi comprising a first strand comprising a first nucleic acid comprising the sequence 5′-UAGACAAUGAUUCACACGGU-3′ (SEQ ID NO:1) and a second strand comprising a second nucleic acid comprising the sequence 5′-ACCGUGUGUCAUUGUCUAA-3′ (SEQ ID NO:2), wherein the A residue at residue 18 or residue 19 of the second strand does not form a basepair with a residue in the first strand.

### Claim 165

A method for inhibiting the accumulation of htt in a cell of a mammal with Huntington's disease comprising administering to the mammal an RNAi comprising a first strand comprising a first nucleic acid comprising the sequence 5′-UAGACAAUGAUUCACACGGU-3′ (SEQ ID NO:1) and a second strand comprising a second nucleic acid comprising the sequence 5′-ACCGUGUGUCAUUGUCUAA-3′ (SEQ ID NO:2), wherein the A residue at residue 18 or residue 19 of the second strand does not form a basepair with a residue in the first strand.

### Claim 166 (depends on 163, 164, 165)

The method of any one of claims 163-165, wherein the first strand comprises a nucleic acid sequence having about 90% identity to SEQ ID NO:1.

### Claim 167 (depends on 163, 164, 165)

The method of any one of claims 163-165, wherein the second strand comprises a nucleic acid sequence having about 90% identity to SEQ ID NO:2.

### Claim 168 (depends on 163, 164, 165, 166, 167)

The method of any one of claims 163-167, wherein the nucleic acid is improved to reduce off-target gene silencing.

### Claim 169 (depends on 163, 164, 165, 166, 167, 168)

The method of any one of claims 163-168, wherein the nucleic acid comprises one or more CpG motifs.

### Claim 170 (depends on 163, 164, 165, 166, 167, 168, 169)

The method of any one of claims 163-169, wherein the nucleic acid comprises one or more CpG motifs in a seed region.

### Claim 171

A method for treating Huntington's disease in a mammal comprising administering to the mammal an RNAi comprising a first strand comprising a first nucleic acid comprising the sequence 5′-UCGACAAUGAUUCACACGGU-3′ (SEQ ID NO:15) and a second strand comprising a second nucleic acid comprising the sequence 5′-ACCGUGUGUCAUUGUCGAA-3′ (SEQ ID NO:16), wherein the A residue at residue 18 or residue 19 of the second strand does not form a basepair with a residue in the first strand.

### Claim 172

A method for inhibiting the expression of htt in a mammal with Huntington's disease comprising administering to the mammal an RNAi comprising a first strand comprising a first nucleic acid comprising the sequence 5′-UCGACAAUGAUUCACACGGU-3′ (SEQ ID NO:15) and a second strand comprising a second nucleic acid comprising the sequence 5′-ACCGUGUGUCAUUGUCGAA-3′ (SEQ ID NO:16), wherein the A residue at residue 18 or residue 19 of the second strand does not form a basepair with a residue in the first strand.

### Claim 173

A method for inhibiting the accumulation of htt in a cell of a mammal with Huntington's disease comprising administering to the mammal an RNAi comprising a first strand comprising a first nucleic acid comprising the sequence 5′-UCGACAAUGAUUCACACGGU-3′ (SEQ ID NO:15) and a second strand comprising a second nucleic acid comprising the sequence 5′-ACCGUGUGUCAUUGUCGAA-3′ (SEQ ID NO:16), wherein the A residue at residue 18 or residue 19 of the second strand does not form a basepair with a residue in the first strand.

### Claim 174 (depends on 171, 172, 173)

The method of any one of claims 171-173, wherein the first strand comprises a nucleic acid sequence having about 90% identity to SEQ ID NO:15 but maintains the CpG motif.

### Claim 175 (depends on 171, 172, 173, 174)

The method of any one of claims 171-174, wherein the second strand comprises a nucleic acid sequence having about 90% identity to SEQ ID NO:16 but maintains the CpG motif.

### Claim 176

A method for treating Huntington's disease in a mammal comprising administering to the mammal an RNAi comprising a first strand comprising a first nucleic acid comprising the sequence 5′-UAGACGAUGAUUCACACGGU-3′ (SEQ ID NO:17) and a second strand comprising a second nucleic acid comprising the sequence 5′-ACCGUGUGUCAUCGUCUAA-3′ (SEQ ID NO:18), wherein the A residue at residue 18 or residue 19 of the second strand does not form a basepair with a residue in the first strand.

### Claim 177

A method for inhibiting the expression of htt in a mammal with Huntington's disease comprising administering to the mammal an RNAi comprising a first strand comprising a first nucleic acid comprising the sequence 5′-UAGACGAUGAUUCACACGGU-3′ (SEQ ID NO:17) and a second strand comprising a second nucleic acid comprising the sequence 5′-ACCGUGUGUCAUCGUCUAA-3′ (SEQ ID NO:18), wherein the A residue at residue 18 or residue 19 of the second strand does not form a basepair with a residue in the first strand.

### Claim 178

A method for inhibiting the accumulation of htt in a cell of a mammal with Huntington's disease comprising administering to the mammal an RNAi comprising a first strand comprising a first nucleic acid comprising the sequence 5′-UAGACGAUGAUUCACACGGU-3′ (SEQ ID NO:17) and a second strand comprising a second nucleic acid comprising the sequence 5′-ACCGUGUGUCAUCGUCUAA-3′ (SEQ ID NO:18), wherein the A residue at residue 18 or residue 19 of the second strand does not form a basepair with a residue in the first strand.

### Claim 179 (depends on 176, 177, 178)

The method of any one of claims 176-178, wherein the first strand comprises a nucleic acid sequence having about 90% identity to SEQ ID NO:17 but maintains the CpG motif.

### Claim 180 (depends on 176, 177, 178, 179)

The method of any one of claims 176-179, wherein the second strand comprises a nucleic acid sequence having about 90% identity to SEQ ID NO:18 but maintains the CpG motif.

### Claim 181 (depends on 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180)

The method of any one of claims 163-180, wherein U residues at residues 11 and 12 of the first nucleic acid do not form a basepair with a residue in the second strand.

### Claim 182 (depends on 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181)

The method of any one of claims 163-181, wherein the duplex is between 18 and 25 base pairs in length.

### Claim 183 (depends on 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182)

The method of any one of claims 163-182, wherein the first and/or second strand further comprises a 3′ overhang region, a 5′ overhang region, or both 3′ and 5′ overhang regions.

### Claim 184 (depends on 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183)

The method of any one of claims 163-183, wherein the first strand and the second strand are linked by means of an RNA capable of forming a loop structure.

### Claim 185 (depends on 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184)

The method of any one of claims 163-184, wherein RNA capable of forming a loop structure comprises from 4 to 50 nucleotides or 4 to 20 nucleotides.

### Claim 186 (depends on 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185)

The method of any one of claims 163-185, wherein RNA capable of forming a loop structure comprises 13 nucleotides.

### Claim 187 (depends on 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186)

The method of any one of claims 163-186, wherein the RNAi comprises the nucleotide sequence of SEQ ID NO:3.

### Claim 188 (depends on 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187)

The method of any one of claims 163-187, wherein the RNAi comprises a nucleotide sequence about 90% identical to the nucleotide sequence of SEQ ID NO:3.

### Claim 189 (depends on 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188)

The method of any one of claims 163-188, wherein the first strand of the RNAi is 5′ to the second strand.

### Claim 190 (depends on 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189)

The method of any one of claims 163-189, wherein the second strand of the RNAi is 5′ to the first strand.

### Claim 191 (depends on 163, 164, 165, 166)

The method of any one of claims 163-166, wherein the RNAi is encoded on an expression construct.

### Claim 192 (depends on 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191)

The method of any one of claims 163-191, wherein the nucleic acid encoding the RNAi comprises a miRNA scaffold.

### Claim 193 (depends on 192)

The method of claim 192, wherein the miRNA scaffold is a miR-155 scaffold.

### Claim 194 (depends on 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193)

The method of any one of claims 163-193, wherein the nucleic acid encoding the RNAi is operably linked to a promoter.

### Claim 195 (depends on 194)

The method of claim 194, wherein the promoter is capable of expressing the RNAi in the brain of a mammal.

### Claim 196 (depends on 195)

The method of claim 195, wherein the promoter is selected from a cytomegalovirus (CMV) immediate early promoter, a RSV LTR, a MoMLV LTR, a phosphoglycerate kinase-1 (PGK) promoter, a simian virus 40 (SV40) promoter, a CK6 promoter, a transthyretin promoter (TTR), a TK promoter, a tetracycline responsive promoter (TRE), an HBV promoter, an hAAT promoter, a LSP promoter, a chimeric liver-specific promoter (LSP), a E2F promoter, a telomerase (hTERT) promoter; a cytomegalovirus enhancer/chicken beta-actin/Rabbit β-globin (CAG) promoter, an elongation factor 1-alpha promoter (EF1-alpha) promoter and a human β-glucuronidase promoter.

### Claim 197 (depends on 194, 195, 196)

The method of any one of claims 194-196, wherein the promoter is a hybrid chicken β-actin promoter.

### Claim 198 (depends on 167, 168, 169, 170, 171, 172, 173)

The method of any one of claims 167-173, wherein the expression construct further comprises a polyadenylation signal.

### Claim 199 (depends on 174)

The method of claim 174, wherein the polyadenylation signal is a bovine growth hormone polyadenylation signal.

### Claim 200 (depends on 191, 192, 193, 194, 195, 196, 197, 198, 199)

The method of any one of claims 191-199, wherein the expression construct is encoded by a vector.

### Claim 201 (depends on 200)

The method of claim 200, wherein the vector is a recombinant adeno-associated virus (rAAV) vector, a recombinant adenoviral vector, a recombinant lentiviral vector or a recombinant herpes simplex virus (HSV) vector.

### Claim 202 (depends on 201)

The method of claim 201, wherein the vector is a recombinant adenoviral vector.

### Claim 203 (depends on 202)

The method of claim 202, wherein the recombinant adenoviral vector is derived from Adenovirus serotype 2, 1, 5, 6, 19, 3, 11, 7, 14, 16, 21, 12, 18, 31, 8, 9, 10, 13, 15, 17, 19, 20, 22, 23, 24-30, 37, 40, 41, AdHu2, AdHu 3, AdHu4, AdHu24, AdHu26, AdHu34, AdHu35, AdHu36, AdHu37, AdHu41, AdHu48, AdHu49, AdHu50, AdC6, AdC7, AdC69, bovine Ad type 3, canine Ad type 2, ovine Ad, or porcine Ad type 3.

### Claim 204 (depends on 203)

The method of claim 203, wherein the recombinant adenoviral vector is derived from adenovirus serotype 2 or a variant of adenoviral serotype 5.

### Claim 205 (depends on 201)

The method of claim 201, wherein the vector is a recombinant lentiviral vector.

### Claim 206 (depends on 205)

The method of claim 205, wherein the recombinant lentiviral vector is derived from a lentivirus pseudotyped with vesicular stomatitis virus (VSV), lymphocytic choriomeningitis virus (LCMV), Ross river virus (RRV), Ebola virus, Marburg virus, Mokala virus, Rabies virus, RD114 or variants therein.

### Claim 207 (depends on 201)

The method of claim 201, wherein the vector is a rHSV vector.

### Claim 208 (depends on 207)

The method of claim 207, wherein the rHSV vector is derived from rHSV-1 or rHSV-2.

### Claim 209 (depends on 201)

The method of claim 201, wherein the vector is a recombinant AAV (rAAV) vector.

### Claim 210 (depends on 209)

The method of claim 209, wherein the expression construct is flanked by one or more AAV inverted terminal repeat (ITR) sequences.

### Claim 211 (depends on 210)

The method of claim 210, wherein the expression construct is flanked by two AAV ITRs.

### Claim 212 (depends on 210, 211)

The method of claim 210 or 211, wherein the AAV ITRs are AAV ITRs are AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAVrh8, AAVrh8R, AAV9, AAV10, AAVrh10, AAV11, AAV12, AAV2R471A, AAV DJ, a goat AAV, bovine AAV, or mouse AAV serotype ITRs.

### Claim 213 (depends on 210, 211, 212)

The method of any one of claims 210-212, wherein the AAV ITRs are AAV2 ITRs.

### Claim 214 (depends on 213)

The method of claim 213, wherein the rAAV vector comprises 5′ to 3′ an AAV2 ITR, a promoter, nucleic acid encoding the RNAi, a polyadenylation signal, and an AAV2 ITR.

### Claim 215 (depends on 214)

The method of claim 214 wherein the promoter is a CBA promoter.

### Claim 216 (depends on 214, 215)

The method of claim 214 or 215, wherein the polyadenylation signal is a bovine growth hormone polyadenylation signal.

### Claim 217 (depends on 213)

The method of claim 213, wherein the rAAV vector comprises 5′ to 3′ an AAV2 ITR, the CBA promoter, nucleic acid encoding the RNAi, a bovine growth hormone polyadenylation signal, and an AAV2 ITR.

### Claim 218 (depends on 217)

The method of claim 217, wherein the vector further comprise a stuffer nucleic acid.

### Claim 219 (depends on 218)

The method of claim 218, wherein the stuffer nucleic acid comprises nucleic acid encoding a green fluorescent protein (GFP).

### Claim 220 (depends on 218, 219)

The method of claim 218 or 219, wherein the stuffer nucleic acid is located between the promoter and the nucleic acid encoding the RNAi.

### Claim 221 (depends on 214, 215, 216, 217, 218, 219, 220)

The method of any one of claims 214-220, wherein the RNAi comprises the nucleotide sequence of SEQ ID NO:3.

### Claim 222 (depends on 214, 215, 216, 217, 218, 219, 220)

The method of any one of claims 214-220, wherein the RNAi comprises a nucleotide sequence about 90% identical to the nucleotide sequence of SEQ ID NO:3.

### Claim 223 (depends on 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222)

The method of any one of claims 209-222, wherein the vector is a self-complimenting vector.

### Claim 224 (depends on 223)

The method of claim 223, wherein the vector comprises first nucleic acid sequence encoding the RNAi and a second nucleic acid sequence encoding a complement of the RNAi, wherein the first nucleic acid sequence can form intrastrand base pairs with the second nucleic acid sequence along most or all of its length.

### Claim 225 (depends on 224)

The method of claim 224, wherein the first nucleic acid sequence and the second nucleic acid sequence are linked by a mutated AAV ITR, wherein the mutated AAV ITR comprises a deletion of the D region and comprises a mutation of the terminal resolution sequence.

### Claim 226 (depends on 200, 201)

The method of claim 200 or 201, wherein the vector is encapsidated in a rAAV particle, the recombinant adenovirus vector is encapsidated in an adenoviral particle, the recombinant lentiviral vector is encapsidated in a lentiviral particle or the recombinant HSV vector is encapsidated in a HSV.

### Claim 227 (depends on 226)

The method of claim 226, wherein the viral particle is an adenovirus particle encapsidating the recombinant adenoviral vector.

### Claim 228 (depends on 227)

The method of claim 227, wherein the adenovirus particle comprises a capsid from Adenovirus serotype 2, 1, 5, 6, 19, 3, 11, 7, 14, 16, 21, 12, 18, 31, 8, 9, 10, 13, 15, 17, 19, 20, 22, 23, 24-30, 37, 40, 41, AdHu2, AdHu 3, AdHu4, AdHu24, AdHu26, AdHu34, AdHu35, AdHu36, AdHu37, AdHu41, AdHu48, AdHu49, AdHu50, AdC6, AdC7, AdC69, bovine Ad type 3, canine Ad type 2, ovine Ad, or porcine Ad type 3.

### Claim 229 (depends on 228)

The method of claim 228, wherein the adenovirus particle comprises an adenovirus serotype 2 capsid or a variant of an adenoviral serotype 5 capsid.

### Claim 230 (depends on 226)

The method of claim 226, wherein the viral particle is a lentiviral particle encapsidating the recombinant lentiviral vector.

### Claim 231 (depends on 230)

The method of claim 230, wherein the lentiviral particle comprises a capsid pseudotyped with vesicular stomatitis virus (VSV), lymphocytic choriomeningitis virus (LCMV), Ross river virus (RRV), Ebola virus, Marburg virus, Mokala virus, Rabies virus, RD114 or variants therein.

### Claim 232 (depends on 226)

The method of claim 226, wherein the viral particle is a HSV particle.

### Claim 233 (depends on 232)

The method of claim 232, wherein the HSV particle is a rHSV-1 particle or a rHSV-2 particle.

### Claim 234 (depends on 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 223, 224, 225)

The method of any one of claims 209-225, wherein the rAAV vector is encapsidated in a recombinant AAV particle.

### Claim 235 (depends on 234)

The method of claim 234, wherein the AAV viral particle comprises an AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAVrh8, AAVrh8R, AAV9, AAV10, AAVrh10, AAV11, AAV12, AAV2R471A, AAV2/2-7m8, AAV DJ, AAV2 N587A, AAV2 E548A, AAV2 N708A, AAV2 V708K, goat AAV, AAV1/AAV2 chimeric, bovine AAV, mouse AAV, or rAAV2/HBoV1 serotype capsid.

### Claim 236 (depends on 234, 235)

The method of claim 234 or 235, wherein the ITR and the capsid of the rAAV viral particle are derived from the same AAV serotype.

### Claim 237 (depends on 234, 235)

The method of claim 234 or 235, wherein the ITR and the capsid of the rAAV viral particles are derived from different AAV serotypes.

### Claim 238 (depends on 234, 235)

The method of any one of claims 234-235, wherein the rAAV viral particle comprises AAV2 capsid.

### Claim 239 (depends on 237)

The method of claim 237, wherein the rAAV viral particle comprises an AAV1 capsid, and wherein the vector comprises AAV2 ITRs.

### Claim 240 (depends on 226, 227, 228, 229, 230, 231, 232, 233, 234, 235, 236, 237, 238, 239, 2226)

A method of any one of claims 2226-239, wherein the viral particle of any one of claims 226-233 or the rAAV particle of any one of claims 234-239 is in a composition.

### Claim 241 (depends on 240)

The method of claim 240, wherein the composition further comprises a pharmaceutically acceptable carrier.

### Claim 242 (depends on 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 223, 224, 225, 226, 227, 228, 229, 230, 231, 232, 233, 234, 235, 236, 237, 238, 239, 240, 241)

Use of the RNAi of any one of claims 86-106; the expression construct of any one of claims 96-104; the vector of any one of claims 116-124; the rAAV vector of any one of claims 125-141; the viral particle of any one of claims 144-151; the rAAV particle of any one of claims 152-157; or the composition of claim 158 or 159, in the manufacture of a medicament for use in the method of any one of claims 160-241.

### Claim 243 (depends on 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 223, 224, 225, 226, 227, 228, 229, 230, 231, 232, 233, 234, 235, 236, 237, 238, 239, 240, 241)

The RNAi of any one of claims 86-106; the expression construct of any one of claims 107-115; the vector of any one of claims 116-124; the rAAV vector of any one of claims 125-141; the viral particle of any one of claims 144-151; the rAAV particle of any one of claims 152-157; or the composition of claim 158 or 159, for use in the method of any one of claims 160-241.

### Claim 244 (depends on 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159)

A kit for inducing RNA interference in a mammal with Huntington's disease comprising the RNAi of any one of claims 86-106; the expression construct of any one of claims 107-115; the vector of any one of claims 116-124; the rAAV vector of any one of claims 125-141; the viral particle of any one of claims 144-151; the rAAV particle of any one of claims 152-157; or the composition of claim 158 or 159.

### Claim 245 (depends on 244)

The kit of claim 244, wherein the mammal is a human.

### Claim 246 (depends on 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 223, 224, 225, 226, 227, 228, 229, 230, 231, 232, 233, 234, 235, 236, 237, 238, 239, 240, 241)

A kit for use in the method of any one of claims 160-241 comprising the RNAi of any one of claims 86-106; the expression construct of any one of claims 107-115; the vector of any one of claims 116-124; the rAAV vector of any one of claims 125-141; the viral particle of any one of claims 144-151; the rAAV particle of any one of claims 152-157; or the composition of claims 158 or 159, in the manufacture of a medicament for use in the method of any one of claims 160-241.
